Sugi Predict

Sugi Predict / Compounds / SCHEMBL574660

SCHEMBL574660

SCHEMBL574660

CSc1ncc2ccc(=O)n(C3CCCC3)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCND1 P24385 18/20 0.56
▸ CDK2 P24941 17/20 0.56
▸ CDK4 P11802 12/20 0.56
▸ CCND2 P30279 9/20 0.56
▸ CCND3 P30281 9/20 0.56
▸ CCNA2 P20248 7/20 0.56
▸ FGFR1 P11362 3/20 0.56
▸ FGFR2 P21802 3/20 0.56
▸ FGFR4 P22455 3/20 0.56
▸ FGFR3 P22607 3/20 0.56
▸ CCNA1 P78396 6/20 0.53
▸ CCNE1 P24864 15/20 0.53
▸ CDK6 Q00534 9/20 0.53
▸ CCNT1 O60563 3/20 0.53
▸ CDK9 P50750 3/20 0.53
▸ CCNE2 O96020 5/20 0.50
▸ CCNB2 O95067 3/20 0.50
▸ CDK1 P06493 3/20 0.50
▸ CCNB1 P14635 3/20 0.50
▸ CCNB3 Q8WWL7 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29990953 1.00 CCND1 (0.56) CCND1CDK2CDK4CCND2CCND3
SCHEMBL5263603 0.99 CCND1 (0.57) CCND1CDK2CDK4CCND2CCND3
SCHEMBL4828470 0.99 CCND1 (0.57) CCND1CDK2CDK4CCND2CCND3
SCHEMBL4828611 0.94 CCND1 (0.49) CCND1CDK2CDK4CCND2CCND3
SCHEMBL31637530 0.94 CCND1 (0.49) CCND1CDK2CDK4CCND2CCND3
SCHEMBL31153373 0.87 CDK2 (0.58) CCND1CDK2CDK4CCND2CCND3
SCHEMBL19857375 0.87 CDK2 (0.58) CCND1CDK2CDK4CCND2CCND3
SCHEMBL29507717 0.85 CCND1 (0.42) CCND1CDK2CDK4CCND2CCND3
SCHEMBL22860605 0.83 CCND1 (0.40) CCND1CDK2CDK4CCND2CCND3
SCHEMBL24669667 0.82 CDK2 (0.53) CCND1CDK2CDK4CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806348-A2 Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation Warner-Lambert Company LLC (US) 2007-07-11 — — EP claimed
US-6498163-B1 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2002-12-24 — — US claimed
EP-0964864-A2 PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-22 — — EP claimed
WO-1998033798-A2 PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION WARNER LAMBERT COMPANY (US) 1998-08-06 — — WO claimed
US-12097261-B2 CDK2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-24 — — US disclosed
US-20240124464-A1 SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2024-04-18 — — US disclosed
CN-117715904-A CDK2 degrading agents and uses thereof 凯麦拉医疗公司 2024-03-15 — — CN disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
WO-2024039903-A2 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 — — WO disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
WO-2023051302-A1 HETEROCYCLIC COMPOUND HAVING CYCLIN-DEPENDENT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2023-04-06 — — WO disclosed
EP-1470124-A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES Warner-Lambert Company LLC (US) 2004-10-27 — — EP disclosed
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones BARVIAN MARK (US) 2003-08-07 — — US disclosed
WO-2003062236-A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 — — WO disclosed
US-6498163-B1 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2002-12-24 — — US disclosed
EP-1255755-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2002-11-13 — — EP disclosed
WO-2001055148-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2001-08-02 — — WO disclosed
EP-0964864-A2 PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-22 — — EP disclosed
WO-1998033798-A2 PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION WARNER LAMBERT COMPANY (US) 1998-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones CDK4, CDK2, CDK1 CCND1 27/4885CDK2 2/4885CDK4 1/4885
US-12097261-B2 CDK2 degraders and uses thereof CDK2, CDK20, CDK1 CCND1 49/4885CDK2 1/4885CDK4 4/4885
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 CCND1 49/4885CDK2 1/4885CDK4 4/4885
US-20240124464-A1 SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF NUAK1, NUAK2, NEK11 CCND1 379/4885CDK2 16/4885CDK4 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.